News Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports

News Annamycin Trial in Poland Permitted to Accelerate Dose Escalation in AML Patients

cystic fibrosis, News, syndicated Video Games Connect Chronically Ill Children Isolated at Home, Hospital

News Phase 3 Trial Stops Testing Idasanutlin in AML Patients Undergoing Chemo

News FDA Reviewing CC-486 as Maintenance Treatment of Adult Patients in Remission

News GT Biopharma Completes Dosing of First Patient in Phase 1/2 Trial of GTB-3550

News Antibody to Treat AML Showing Safety and Clinical Activity in Early Trial Data

News COVID-19 Pandemic Stops Phase 2 Trial of Ficlatuzumab Combo Therapy for AML

News FDA Grants Orphan Drug Status to SEL120 for Acute Myeloid Leukemia

News Cancer Vaccine Galinpepimut-S Prolongs Life of Patients with AML, Results of Pilot Trial Show

News NORD’s Advice on COVID-19: You’re Stronger Than You Think

News Actimab-A and Chemo Combo Showing Promise in Advanced AML Patients

News NORD Partners with ‘Sing Me a Story’ for July 18–20 Living Rare Forum

News Global Rare Disease Group’s Focus: 1,000 New Therapies by 2027, Despite COVID-19

News Venclexta-Cytarabine Fails to Significantly Prolong Life in Untreated AML Patients, Trial Shows

News Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News Phase 2 Trial of Annamycin, as Less Toxic Chemo, in Advanced AML Planned

News Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News Elsevier Opens Books, Review Articles to Rare Disease Researchers Starting Feb. 29

News Medigene’s AML Cancer Vaccine Shows Positive Results in Clinical Trial

News Advice on Starting Nonprofit Groups for Rare and Other Diseases Focus of NORD Webinar

News Patients, Supporters Worldwide Recognizing Rare Disease Day 2020

News First Patient Dosed in Phase 2 Trial of Alvocidib for Relapsed or Refractory AML, Tolero Says

News FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar

News With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus

News First AML Patient Dosed in Phase 1 Trial of Cellectis’ CAR T-cell Therapy, UCART123

News Computers Can Quickly See Patterns in Data to Diagnose Ills Like AML, Study Suggests

News Sellas Begins Screening AML Patients for Phase 3 Trial Testing Cancer Vaccine Galinpepimut-S

News FDA Grants Orphan Drug Status to Precigen’s Investigational PRGN-3006 CAR-T Cell Therapy for AML

News Flotetuzumab Puts A Third of Hard-to-treat AML Patients in Remission, Phase 1/2 Data Show

News AB Science’s Small Molecule Treatment for AML Named Orphan Drug by FDA, 1st Trial Planned

News HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

News Rare Disease Film Festival Highlights Patient and Researcher Unity

News Quizartinib Not Recommended in Europe as Therapy for Relapsed or Refractory AML with FLT3-ITD Mutation

News Bemcentinib Earns FDA Fast Track Designation for Elderly Patients with Relapsed AML

News European Commission Approves Xospata for AML Patients with Certain Genetic Mutation

News CC-486 as Maintenance Therapy Extends Survival in AML Patients, Phase 3 Trial Shows